The latest in cancer prevention, diagnosis & treatment
Halaven Approved for Late-Stage Breast Cancers
The Food and Drug Administration approved Halaven (eribulin) on Nov. 15 to treat metastatic breast cancer patients who have already tried at least two chemotherapy treatments.
Halaven is an injectable synthetic compound derived from the sea sponge Halichondria okadai. It’s a microtubule inhibitor that works by preventing cancer cells from dividing.
The decision comes after a phase 3 clinical trial found that Halaven extended median survival in patients with metastatic breast cancer who had already tried other treatments. Researchers presented the results of the trial at the annual meeting of the American Society of Clinical Oncology, stating that this is the first time a single agent has helped these previously treated patients live longer.
The Food and Drug Administration approved Halaven (eribulin) on Nov. 15 to treat metastatic breast cancer patients who have already tried at least two chemotherapy treatments.
Halaven is an injectable synthetic compound derived from the sea sponge Halichondria okadai. It’s a microtubule inhibitor that works by preventing cancer cells from dividing.
The decision comes after a phase 3 clinical trial found that Halaven extended median survival in patients with metastatic breast cancer who had already tried other treatments. Researchers presented the results of the trial at the annual meeting of the American Society of Clinical Oncology, stating that this is the first time a single agent has helped these previously treated patients live longer.
Posts
